Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Fonager, Randi Fuglsang ; Zacho, Helle Damgaard ; Langkilde, Niels Christian ; Fledelius, Joan ; Ejlersen, June Anita ; Hendel, Helle Westergreen ; Haarmark, Christian ; Moe, Mette ; Mortensen, Jesper Carl ; Jochumsen, Mads Ryø ; Petersen, Lars Jelstrup. / Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. I: Acta oncologica . 2018 ; Bind 57, Nr. 8. s. 1063-1069.

Bibtex

@article{e5e68373faa742ec853e173614324269,
title = "Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer",
abstract = "AIM: To compare 18F-sodium fluoride positron emission tomography/computed tomography (NaF PET/CT) and 99mTc-labelled diphosphonate bone scan (BS) for the monitoring of bone metastases in patients with prostate cancer undergoing anti-cancer treatment.MATERIAL AND METHODS: Data from 64 patients with prostate cancer were included. The patients received androgen-deprivation therapy (ADT), next-generation hormonal therapy (NGH) or chemotherapy. The patients had a baseline scan and 1-3 subsequent scans during six months of treatment. Images were evaluated by experienced nuclear medicine physicians and classified for progressive disease (PD) or non-PD according to the Prostate Cancer Working Group 2 (PCWG-2) criteria. The patients were also classified as having PD/non-PD according to the clinical and prostate-specific antigen (PSA) responses.RESULTS: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD during treatment (McNemar's test, p = .18). The agreement between BS and NaF PET/CT for PD/non-PD was moderate (Cohen's kappa 0.53, 95% confidence interval 0.26-0.79). Crude agreement between BS and NaF PET/CT for the assessment of PD/non-PD was 86% (89% for ADT, n = 28; 88% for NGH, n = 16, and 80% for chemotherapy, n = 20). In most discordant cases, BS found PD when NaF PET/CT did not, or BS detected PD on an earlier scan than NaF PET/CT. Biochemical progression (27%) occurred more frequently than progression on functional imaging (BS, 22% and NaF PET/CT, 14%). Clinical progression was rare (11%), and almost exclusively seen in patients receiving chemotherapy.CONCLUSION: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan.",
keywords = "Aged, Aged, 80 and over, Bone Neoplasms/diagnostic imaging, Fluorine Radioisotopes, Humans, Male, Middle Aged, Positron Emission Tomography Computed Tomography/methods, Prospective Studies, Prostatic Neoplasms/drug therapy, Radionuclide Imaging/methods, Radiopharmaceuticals, Sodium Fluoride, Treatment Outcome",
author = "Fonager, {Randi Fuglsang} and Zacho, {Helle Damgaard} and Langkilde, {Niels Christian} and Joan Fledelius and Ejlersen, {June Anita} and Hendel, {Helle Westergreen} and Christian Haarmark and Mette Moe and Mortensen, {Jesper Carl} and Jochumsen, {Mads Ry{\o}} and Petersen, {Lars Jelstrup}",
year = "2018",
month = aug,
doi = "10.1080/0284186X.2018.1438651",
language = "English",
volume = "57",
pages = "1063--1069",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "8",

}

RIS

TY - JOUR

T1 - Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer

AU - Fonager, Randi Fuglsang

AU - Zacho, Helle Damgaard

AU - Langkilde, Niels Christian

AU - Fledelius, Joan

AU - Ejlersen, June Anita

AU - Hendel, Helle Westergreen

AU - Haarmark, Christian

AU - Moe, Mette

AU - Mortensen, Jesper Carl

AU - Jochumsen, Mads Ryø

AU - Petersen, Lars Jelstrup

PY - 2018/8

Y1 - 2018/8

N2 - AIM: To compare 18F-sodium fluoride positron emission tomography/computed tomography (NaF PET/CT) and 99mTc-labelled diphosphonate bone scan (BS) for the monitoring of bone metastases in patients with prostate cancer undergoing anti-cancer treatment.MATERIAL AND METHODS: Data from 64 patients with prostate cancer were included. The patients received androgen-deprivation therapy (ADT), next-generation hormonal therapy (NGH) or chemotherapy. The patients had a baseline scan and 1-3 subsequent scans during six months of treatment. Images were evaluated by experienced nuclear medicine physicians and classified for progressive disease (PD) or non-PD according to the Prostate Cancer Working Group 2 (PCWG-2) criteria. The patients were also classified as having PD/non-PD according to the clinical and prostate-specific antigen (PSA) responses.RESULTS: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD during treatment (McNemar's test, p = .18). The agreement between BS and NaF PET/CT for PD/non-PD was moderate (Cohen's kappa 0.53, 95% confidence interval 0.26-0.79). Crude agreement between BS and NaF PET/CT for the assessment of PD/non-PD was 86% (89% for ADT, n = 28; 88% for NGH, n = 16, and 80% for chemotherapy, n = 20). In most discordant cases, BS found PD when NaF PET/CT did not, or BS detected PD on an earlier scan than NaF PET/CT. Biochemical progression (27%) occurred more frequently than progression on functional imaging (BS, 22% and NaF PET/CT, 14%). Clinical progression was rare (11%), and almost exclusively seen in patients receiving chemotherapy.CONCLUSION: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan.

AB - AIM: To compare 18F-sodium fluoride positron emission tomography/computed tomography (NaF PET/CT) and 99mTc-labelled diphosphonate bone scan (BS) for the monitoring of bone metastases in patients with prostate cancer undergoing anti-cancer treatment.MATERIAL AND METHODS: Data from 64 patients with prostate cancer were included. The patients received androgen-deprivation therapy (ADT), next-generation hormonal therapy (NGH) or chemotherapy. The patients had a baseline scan and 1-3 subsequent scans during six months of treatment. Images were evaluated by experienced nuclear medicine physicians and classified for progressive disease (PD) or non-PD according to the Prostate Cancer Working Group 2 (PCWG-2) criteria. The patients were also classified as having PD/non-PD according to the clinical and prostate-specific antigen (PSA) responses.RESULTS: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD during treatment (McNemar's test, p = .18). The agreement between BS and NaF PET/CT for PD/non-PD was moderate (Cohen's kappa 0.53, 95% confidence interval 0.26-0.79). Crude agreement between BS and NaF PET/CT for the assessment of PD/non-PD was 86% (89% for ADT, n = 28; 88% for NGH, n = 16, and 80% for chemotherapy, n = 20). In most discordant cases, BS found PD when NaF PET/CT did not, or BS detected PD on an earlier scan than NaF PET/CT. Biochemical progression (27%) occurred more frequently than progression on functional imaging (BS, 22% and NaF PET/CT, 14%). Clinical progression was rare (11%), and almost exclusively seen in patients receiving chemotherapy.CONCLUSION: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan.

KW - Aged

KW - Aged, 80 and over

KW - Bone Neoplasms/diagnostic imaging

KW - Fluorine Radioisotopes

KW - Humans

KW - Male

KW - Middle Aged

KW - Positron Emission Tomography Computed Tomography/methods

KW - Prospective Studies

KW - Prostatic Neoplasms/drug therapy

KW - Radionuclide Imaging/methods

KW - Radiopharmaceuticals

KW - Sodium Fluoride

KW - Treatment Outcome

U2 - 10.1080/0284186X.2018.1438651

DO - 10.1080/0284186X.2018.1438651

M3 - Journal article

C2 - 29447047

VL - 57

SP - 1063

EP - 1069

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 8

ER -

ID: 56147502